As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Treatment Study for Patients with Non-Alcoholic Steatohepatitis and Liver Fibrosis
The purpose of this study is to determine the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with nonalcoholic steatohepatitis (NASH). 2000 subjects will be recruited for this study. At Rush University Medical Center, we expect to recruit 5 subjects. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Have histological diagnosis of NASH.
- Have liver fibrosis stage 2 or 3.
You will be excluded from the study if any of the following criteria apply to you:
- Have liver cirrhosis.
- Have other known causes of liver diseases.
- Have prior liver transplantation
This is a partial list of inclusion and exclusion criteria.